All In Biotech

Drug Trial Radar · NCT00972283

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

NN1250-3582: A 52-week Randomised, Controlled, Open Label, Multicentre, Multinational Treat-to-target Trial Comparing Efficacy and Safety of SIBA and Insulin Glargine Both Administered Once Daily in a Basal-bolus Regimen With Insulin Aspart as Mealtime Insulin ± Treatment With Metformin, ± Pioglitazone in Subjects With Type 2 Diabetes Currently Treated With Insulin Qualifying for Intensified Treatment/NN1250-3667: An Extension Trial to NN1250-3582 Comparing Safety and Efficacy of NN1250 and Insulin Glargine, Both With Insulin Aspart as Meal-time Insulin ± OADs in Type 2 Diabetes (BEGIN™: BB)

Last checked: Nov 19, 2026Latest source record: Apr 6, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,006 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,006

Actual

Start

Sep 1, 2009

Primary completion

Oct 28, 2010

Study completion Oct 28, 2010

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Sep 4, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Africa, Asia, Europe, and the United States of America (USA). The aim of this clinical trial is to compare NN1250 (insulin degludec (IDeg)) with insulin glargine (IGlar) plus insulin aspart (IAsp) with/without metformin and with/without pioglitazone in subjects with type 2 diabetes (main period) followed by investigating the long-term safety in terms of comparing NN1250 with insulin glargine plus insulin aspart with or without metformin and with or without pioglitazone in subjects with type 2 diabetes. All oral anti-diabetic drug (OAD) treatment will be discontinued, if applicable, when trial participant enters the trial (NN1250-3582) with the exception of metformin and pioglitazone. Subjects who consent to participate in the extension trial (NN1250-3667) will continue to receive the treatment to which they were randomly allocated in the 52 week trial NN1250-3582. The main period is registered internally at Novo Nordisk as NN1250-3582 while the extension period is registered as NN1250-3667.

Conditions

  • Diabetes
  • Diabetes Mellitus, Type 2

Interventions

  • insulin degludecDrug

    Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.

  • insulin glargineDrug

    Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.

  • insulin aspartDrug

    Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Main Trial (Primary Endpoint): Change in Glycosylated Haemoglobin (HbA1c) After 52 Weeks of TreatmentTime frame: Week 0, Week 52
  2. Extension Trial (Primary Endpoint): Rate of Confirmed Hypoglycaemic EpisodesTime frame: Week 0 to Week 78 + 7 days follow up
  3. Extension Trial (Primary Endpoint): Rate of Nocturnal Confirmed Hypoglycaemic EpisodesTime frame: Week 0 to Week 78 + 7 days follow up
  4. Rate of Treatment Emergent Adverse Events (AEs)Time frame: Week 0 to Week 78 + 7 days follow up

Locations

136 sites in 12 countries. Site status is shown where the registry gives one.

  • Novo Nordisk Investigational Site

    Alexander City, Alabama

  • Novo Nordisk Investigational Site

    Birmingham, Alabama

  • Novo Nordisk Investigational Site

    Goodyear, Arizona

  • Novo Nordisk Investigational Site

    Peoria, Arizona

  • Novo Nordisk Investigational Site

    Anaheim, California

  • Novo Nordisk Investigational Site

    Huntington Beach, California

  • Novo Nordisk Investigational Site

    Los Gatos, California

  • Novo Nordisk Investigational Site

    Salinas, California

  • Novo Nordisk Investigational Site

    Santa Monica, California

  • Novo Nordisk Investigational Site

    Spring Valley, California

  • Novo Nordisk Investigational Site

    Tustin, California

  • Novo Nordisk Investigational Site

    Walnut Creek, California

  • Novo Nordisk Investigational Site

    Milford, Connecticut

  • Novo Nordisk Investigational Site

    Norwalk, Connecticut

  • Novo Nordisk Investigational Site

    Waterbury, Connecticut

  • Novo Nordisk Investigational Site

    Washington D.C., District of Columbia

  • Novo Nordisk Investigational Site

    Gainesville, Florida

  • Novo Nordisk Investigational Site

    Jacksonville, Florida

  • Novo Nordisk Investigational Site

    Lake Mary, Florida

  • Novo Nordisk Investigational Site

    Orlando, Florida

  • Novo Nordisk Investigational Site

    Plantation, Florida

  • Novo Nordisk Investigational Site

    West Palm Beach, Florida

  • Novo Nordisk Investigational Site

    Atlanta, Georgia

  • Novo Nordisk Investigational Site

    Fort Valley, Georgia

  • Novo Nordisk Investigational Site

    Honolulu, Hawaii

  • Novo Nordisk Investigational Site

    Nampa, Idaho

  • Novo Nordisk Investigational Site

    Evansville, Indiana

  • Novo Nordisk Investigational Site

    Indianapolis, Indiana

  • Novo Nordisk Investigational Site

    New Albany, Indiana

  • Novo Nordisk Investigational Site

    Metairie, Louisiana

  • Novo Nordisk Investigational Site

    Metairie, Louisiana

  • Novo Nordisk Investigational Site

    Hyattsville, Maryland

  • Novo Nordisk Investigational Site

    North East, Maryland

  • Novo Nordisk Investigational Site

    Rockville, Maryland

  • Novo Nordisk Investigational Site

    Eagan, Minnesota

  • Novo Nordisk Investigational Site

    Jefferson City, Missouri

  • Novo Nordisk Investigational Site

    St Louis, Missouri

  • Novo Nordisk Investigational Site

    Lincoln, Nebraska

  • Novo Nordisk Investigational Site

    Omaha, Nebraska

  • Novo Nordisk Investigational Site

    Las Vegas, Nevada

Showing 40 of 136 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.